Can I Take Reishi Mushroom With Repatha (Evolocumab)?

What Is Repatha and Who Typically Uses It?

Repatha (evolocumab) is a fully human monoclonal antibody that inhibits PCSK9, a protein that degrades LDL receptors on liver cells. By blocking PCSK9, evolocumab keeps more LDL receptors active, driving LDL-cholesterol down by roughly 60 percent from baseline in most patients.

The FDA approved evolocumab in August 2015 for adults with familial hypercholesterolemia (FH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL lowering beyond what statins provide. It is given as a 140 mg subcutaneous injection every two weeks, or 420 mg once monthly.

Why women are a distinct population here

Cardiovascular disease is the number-one killer of women in the United States, yet women were underrepresented in the FOURIER trial, the landmark 27,564-patient study that established evolocumab's cardiovascular mortality benefit. Women made up only about 25 percent of FOURIER participants. That gap matters: female-pattern ASCVD often presents later in life and overlaps with the hormonal shifts of perimenopause and post-menopause, when LDL tends to rise and cardiovascular risk accelerates.

Women with heterozygous familial hypercholesterolemia are diagnosed less often and treated less aggressively than men, even though FH affects approximately one in 250 people regardless of sex. If you are postmenopausal with elevated LDL and established ASCVD, evolocumab is frequently the next step when a statin plus ezetimibe has not reached your LDL goal.

PCOS, metabolic syndrome, and early statin need

Women with polycystic ovary syndrome (PCOS) carry a higher prevalence of dyslipidemia and insulin resistance, and some reach statin-level cardiovascular risk in their thirties. A small subset with PCOS and very high LDL may eventually need PCSK9 inhibition. If that is your situation, the reishi question is directly relevant to you.

What Is Reishi Mushroom and Why Do Women Take It?

Reishi (Ganoderma lucidum) is a woody fungus used in traditional East Asian medicine for centuries. Modern supplement consumers take it for immune support, stress reduction, sleep quality, and, increasingly, for its purported cholesterol-lowering effects.

Active compounds and mechanisms

Reishi contains three main bioactive classes:

• Polysaccharides (beta-glucans): stimulate innate and adaptive immune cells, including natural killer cells and macrophages
• Triterpenes (ganoderic acids): shown in preclinical models to inhibit HMG-CoA reductase and modulate lipid metabolism
• Peptidoglycans: lesser-studied; may contribute to immune signaling

A 2019 systematic review in PLOS ONE that examined 5 randomized trials (n = 398 total) found no statistically significant effect of reishi on LDL-C or total cholesterol in humans, despite promising cell-culture and animal data. The evidence for cholesterol lowering in people is, frankly, thin.

Why women specifically reach for reishi

Women in perimenopause and post-menopause often turn to mushroom-based adaptogens because they are marketed as "hormone-balancing" or "stress-modulating." Reishi is heavily marketed alongside other adaptogens for fatigue, poor sleep, and hot flash-adjacent symptoms. These are understandable motivations. The problem is that "natural" does not mean interaction-free.

The Interaction: Pharmacodynamic, Not Pharmacokinetic

This is the most clinically important section, so let's be direct.

Evolocumab is a monoclonal antibody. It is not metabolized by CYP450 enzymes. It does not use P-glycoprotein transporters. Classical pharmacokinetic herb-drug interactions (the kind that matter with warfarin, statins, and many oral drugs) are essentially irrelevant here. Reishi does not change how Repatha is absorbed, distributed, or eliminated.

The concern is pharmacodynamic: both agents act on overlapping biological pathways, and those overlapping actions can amplify each other's effects or introduce new risks.

Concern 1: Immune modulation

Evolocumab modulates PCSK9, which has roles beyond cholesterol. PCSK9 is expressed on immune cells and may influence inflammatory signaling. Reishi's beta-glucans are potent immune activators. A 2012 study in Immunological Investigations demonstrated that Ganoderma lucidum polysaccharides significantly upregulate T-lymphocyte and dendritic cell activity in humans.

Adding an immune-stimulating supplement to a biologic therapy that already alters immune-adjacent pathways raises a theoretical concern: unpredictable immune activation in patients whose immune systems are already medically managed. This concern is heightened if you are also on another biologic or an immunosuppressant.

Concern 2: Anticoagulant potentiation

This is the more immediately practical risk. Reishi has demonstrated antiplatelet and anticoagulant activity in human studies. A study published in Molecular Pharmacology showed that Ganoderma lucidum extracts inhibit platelet aggregation by suppressing thromboxane B2 synthesis.

Evolocumab itself does not directly affect coagulation. But many women on Repatha for established ASCVD are also on aspirin, clopidogrel, or anticoagulants like apixaban. Adding reishi to that stack compounds antiplatelet effects. Bruising, prolonged bleeding from minor cuts, and spontaneous bleeding are realistic risks in this scenario.

Concern 3: Hepatotoxicity signal

Reishi is generally considered low-hepatotoxic risk in standard doses, but case reports exist. The LiverTox database maintained by the NIH documents rare cases of reishi-associated hepatocellular injury, typically with high-dose powdered reishi taken for extended periods. Evolocumab has an excellent liver-safety profile, but any supplement that stresses hepatic function is worth monitoring when you are on a long-term biologic.

What the Evidence Actually Shows (and What It Does Not)

To organize the evidence clearly, here is a four-level framework for evaluating any supplement-biologic interaction, applied to reishi plus evolocumab:

| Evidence Level | What It Tells You | Reishi + Evolocumab Status | |---|---|---| | Level 1: RCT in humans | Direct interaction proof | None exists | | Level 2: Pharmacokinetic study | Absorption/elimination changes | Not applicable (no CYP450 involvement) | | Level 3: Mechanistic plausibility | Overlapping biological pathways | YES (immune + antiplatelet) | | Level 4: Case reports | Signal detection | Sparse; no documented Repatha-reishi adverse events reported in the FDA FAERS database as of mid-2025 |

The honest answer is that there is no Level 1 or Level 2 evidence to work from. The interaction concern is based entirely on Level 3 mechanistic reasoning. That does not make it imaginary. Most supplement-drug interactions are never studied in dedicated trials, and mechanistic plausibility is the clinically appropriate basis for precaution when the safety stakes are high, as they are in women managing established ASCVD or FH.

Women have been historically underrepresented in both cardiovascular trials and supplement-interaction studies. Almost none of the reishi pharmacology literature specifies female participants or controls for hormonal status. The data available to your clinician is largely extrapolated from male or mixed-sex samples. That is a real gap, and it should be named plainly.

Pregnancy, Lactation, and Contraception

This section is required for any drug article, and it is particularly relevant because some women on PCSK9 inhibitors are of reproductive age (especially those with FH who start treatment in their twenties or thirties, or women with early ASCVD related to PCOS or metabolic syndrome).

Evolocumab in pregnancy

The FDA label for evolocumab states that adequate and well-controlled studies in pregnant women do not exist. Animal studies using doses comparable to human exposure showed no embryo-fetal harm, but monoclonal antibodies actively cross the placenta during the second and third trimester via neonatal Fc receptor transport.

The American College of Obstetricians and Gynecologists (ACOG) and most lipidology guidelines recommend stopping PCSK9 inhibitors before a planned pregnancy or as soon as pregnancy is confirmed, because LDL lowering in mid-to-late pregnancy may theoretically impair fetal cholesterol synthesis, which is essential for neurological development.

If you are a woman with FH of reproductive age, you and your clinician should discuss contraception explicitly. Evolocumab does not interact with hormonal contraceptives, but the half-life of evolocumab is approximately 11 to 17 days, meaning measurable drug exposure persists for weeks after the last dose.

Reishi in pregnancy

There are no adequate human safety data on reishi mushroom in pregnancy. Preclinical data from animal models are mixed; some triterpene fractions showed embryotoxic effects in rodent studies. The absence of safety data is itself a reason to avoid reishi during pregnancy.

Lactation

Evolocumab has not been studied in human breast milk. Given its molecular size (a large monoclonal antibody), oral absorption by an infant is likely to be minimal, but this has not been formally tested. Most conservative guidelines recommend avoiding PCSK9 inhibitors while breastfeeding until data exist.

Reishi transfer into human breast milk is also completely unstudied. Avoid both until more is known.

Who This Is Right For (and Who Should Skip It)

Women who should avoid reishi while on Repatha

• You are also on an anticoagulant (warfarin, apixaban, rivaroxaban) or antiplatelet therapy (aspirin, clopidogrel). The additive anticoagulant risk is the most concrete reason to avoid reishi.
• You are on any immunosuppressant or another biologic. Adding an immune stimulant is counterproductive and potentially destabilizing.
• You are pregnant or trying to conceive. Avoid both agents.
• You are breastfeeding.
• You have pre-existing liver disease or abnormal liver function tests.

Women for whom the risk may be lower and a conversation is reasonable

• You are postmenopausal with stable, well-controlled ASCVD on Repatha monotherapy, not on anticoagulants, with normal liver function, and you want to take a low-dose standardized reishi extract for immune support or sleep.
• You have spoken with your prescribing clinician AND your pharmacist and both are aware of the combination.
• You are willing to monitor: check a CBC and liver function panel at baseline and again after 8 to 12 weeks.

Even in this lower-risk scenario, routine use is not recommended. The absence of evidence of harm is not the same as evidence of safety. The approach should be: document the decision, set a monitoring plan, and revisit at the next cardiology or lipid-management visit.

Practical Monitoring If You Are Already Taking Both

Some women will read this after they have already been combining reishi and Repatha. Here is what to do:

Step 1: Tell your prescriber immediately

Do not discontinue anything abruptly without guidance, but do disclose. Clinicians cannot help you with drug-supplement interactions they do not know about. Supplement non-disclosure is extremely common; a 2017 survey in JAMA Internal Medicine found that 69 percent of patients did not disclose supplement use to their prescribing physician.

Step 2: Check baseline labs

Request a complete blood count (to assess platelet count and detect any immune abnormality), a comprehensive metabolic panel (liver function, specifically ALT and AST), and a fasting lipid panel to confirm your LDL-C is where it should be on Repatha.

Step 3: Watch for these symptoms

Seek same-day care for:

• Unusual bruising or prolonged bleeding from a minor cut
• Blood in urine or stool
• Jaundice (yellow tinge to skin or eyes)
• Significant fatigue or right-upper-quadrant abdominal pain (liver warning signs)

Step 4: Evaluate whether reishi is achieving its intended goal

Given that the PLOS ONE 2019 meta-analysis showed no significant LDL-C reduction with reishi in humans, if you are taking reishi specifically for cholesterol management, you should know that Repatha alone is doing the heavy lifting. The clinical utility of adding reishi for lipid benefit is not supported by current evidence.

Life-Stage Considerations Across the Spectrum

Reproductive years (ages 20 to 40)

Women in this age group most likely to be on Repatha have heterozygous or homozygous FH, diagnosed early, or early-onset ASCVD. Contraception counseling is essential. Reishi is unwise in this group if pregnancy is possible.

Perimenopause (ages 40 to 52, variable)

LDL-C tends to rise significantly during perimenopause as estrogen levels fall. Some women who were previously statin-managed become candidates for add-on PCSK9 inhibition during this window. Perimenopausal women are also the most likely to turn to adaptogens, herbal supplements, and mushroom extracts for sleep and mood support. This is the age group where the reishi-Repatha question is most commonly asked in clinical practice. The cardiovascular stakes are rising, and vigilance about supplement interactions should rise with them.

The Menopause Society (formerly NAMS) does not have a specific position statement on reishi, but its cardiovascular health guidance emphasizes individualized risk assessment and highlights that women in perimenopause face a period of heightened cardiovascular vulnerability.

Post-menopause (ages 55 and older)

This is the highest-risk group for ASCVD and the most common demographic for Repatha prescriptions among women. Post-menopausal women are also more likely to be on concurrent antiplatelet or anticoagulant therapy, which makes the reishi anticoagulant potentiation concern most acute here. A postmenopausal woman on Repatha plus apixaban who adds high-dose reishi is the scenario most likely to produce a clinically meaningful adverse event.

A Note on Reishi Product Quality

Even setting aside the interaction question, the reishi supplement market is poorly regulated. A 2017 study in Scientific Reports found significant variation in beta-glucan content between commercial reishi products, with some containing less than 10 percent of the labeled potency. Adulteration with other Ganoderma species is common.

If you do proceed with reishi for any reason, choose a product with a USP, NSF International, or ConsumerLab verification seal, and look for a standardized extract that specifies the percentage of polysaccharides and triterpenes. Whole-mushroom powder and mycelium-only products behave pharmacologically differently, and most clinical studies used aqueous extracts of the fruiting body, not mycelium.

What Your Prescriber Needs to Know

When you bring this up at your next appointment, these are the four questions worth asking your cardiologist, internist, or lipid specialist:

1. Given my current antiplatelet or anticoagulant regimen, what is my bleeding risk if I add reishi?
2. Is my LDL-C goal being met on Repatha alone, and would adding any supplement affect that monitoring picture?
3. Do I need baseline LFTs before experimenting with any herbal supplement?
4. Is there a dose or form of reishi you would consider lower-risk than others if I still want to try it?

Your pharmacist is also an excellent first point of contact. Clinical pharmacists are specifically trained in drug-supplement interactions and can run a formal interaction check in databases like Natural Medicines Comprehensive Database, which rates the evolocumab-reishi combination as having insufficient evidence for a definitive interaction classification but flags the anticoagulant concern.